Literature DB >> 29345496

Feedback from the European Bioanalysis Forum: focus workshop on current analysis of immunogenicity: best practices and regulatory hurdles.

Joanne Goodman1, Simon Cowen2, Viswanath Devanarayan3, David Egging4, Thomas Emrich5, Michaela Golob6, Daniel Kramer7, Jim McNally8, James Munday9, Robert Nelson10, João A Pedras-Vasconcelos11, Timo Piironen12, Denise Sickert13, Venke Skibeli14, Marianne Scheel Fjording15, Philip Timmerman16.   

Abstract

European Bioanalysis Forum Workshop, Lisbon, Portugal, September 2016: At the recent European Bioanalysis Forum Focus Workshop, 'current analysis of immunogenicity: best practices and regulatory hurdles', several important challenges facing the bioanalytical community in relation to immunogenicity assays were discussed through a mixture of presentations and panel sessions. The main areas of focus were the evolving regulatory landscape, challenges of assay interferences from either drug or target, cut-point setting and whether alternative assays can be used to replace neutralizing antibody assays. This workshop report captures discussions and potential solutions and/or recommendations made by the speakers and delegates.

Keywords:  antidrug antibody (ADA); cut-point; drug tolerance; immunogenicity; neutralizing antibodies; regulatory guidance; target interference

Mesh:

Substances:

Year:  2018        PMID: 29345496     DOI: 10.4155/bio-2017-4971

Source DB:  PubMed          Journal:  Bioanalysis        ISSN: 1757-6180            Impact factor:   2.681


  2 in total

1.  Recommendations for the Development and Validation of Immunogenicity Assays in Support of Biosimilar Programs.

Authors:  Francesca Civoli; Aparna Kasinath; Xiao-Yan Cai; Meenu Wadhwa; Andrew Exley; Philip Oldfield; Safa Alvandkouhi; Gregor Schaffar; John Chappell; Ronald Bowsher; Viswanath Devanarayan; Joseph Marini; Shannon Rebarchak; Michael Anderson; Vera Koppenburg; Todd Lester
Journal:  AAPS J       Date:  2019-12-02       Impact factor: 4.009

2.  Comparison of the ELISA and ECL Assay for Vedolizumab Anti-drug Antibodies: Assessing the Impact on Pharmacokinetics and Safety Outcomes of the Phase 3 GEMINI Trials.

Authors:  Timothy Wyant; Lili Yang; Maria Rosario
Journal:  AAPS J       Date:  2020-11-16       Impact factor: 4.009

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.